JaLCDOI 10.18926/AMO/54600
FullText URL 70_5_397.pdf
Author Akagi, Satoshi| Nakamura, Kazufumi| Akagi, Teiji| Nakagawa, Koji| Takaya, Yoichi| Sarashina, Toshihiro| Ejiri, Kentaro| Ito, Hiroshi|
Abstract A treatment strategy for patients with pulmonary hypertension (PH) and atrial septal defect (ASD) remains unclear. This study was designed to evaluate the effects of initial repair of ASD followed by treatment with PH-specific drugs in patients with PH and ASD. Eligible patients receive transcatheter ASD closure followed by treatment with bosentan and sildenafil. Right heart catheterization is performed at baseline and at 12, 24 and 48 weeks. The primary endpoint is change in pulmonary artery pressure and pulmonary vascular resistance from baseline to follow-up. This study should provide valuable information to establish a therapeutic strategy for PH and ASD.
Keywords pulmonary hypertension atrial septal defect repair and treat transcatheter closure
Amo Type Clinical Study Protocols
Published Date 2016-10
Publication Title Acta Medica Okayama
Volume volume70
Issue issue5
Publisher Okayama University Medical School
Start Page 397
End Page 400
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 27777434
Web of Sience KeyUT 000388098700011
JaLCDOI 10.18926/AMO/53519
FullText URL 69_3_129.pdf
Author Akagi, Satoshi| Nakamura, Kazufumi| Matsubara, Hiromi| Ogawa, Aiko| Sarashina, Toshihiro| Ejiri, Kentaro| Ito, Hiroshi|
Abstract Pulmonary arterial hypertension (PAH) is characterized by elevation of pulmonary artery pressure caused by pulmonary vasoconstriction and vascular remodeling, which leads to right heart failure and death. Epoprostenol (prostaglandin I2) has a potent short-acting vasodilator property, and intravenous continuous epoprostenol is therefore used for treatment of PAH. Here we review evidence for the usefulness of intravenous continuous epoprostenol therapy in patients with PAH. Epoprostenol therapy is effective in idiopathic PAH patients and in patients with PAH associated with connective tissue disease, portal hypertension or congenital heart diseases, but it is not effective in patients with pulmonary veno-occlusive disease or pulmonary capillary hemangiomatosis. High-dose epoprostenol therapy markedly improved hemodynamics in some patients with PAH, possibly due to reverse remodeling of pulmonary arteries. This therapy has several side effects and complications such as headache, hypotension and catheter-related infections. Intravenous continuous epoprostenol is an effective treatment, but there are still some problems to be resolved.
Keywords pulmonary arterial hypertension epoprostenol high-dose complications side effects
Amo Type Review
Published Date 2015-06
Publication Title Acta Medica Okayama
Volume volume69
Issue issue3
Publisher Okayama University Medical School
Start Page 129
End Page 136
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2015 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 26101188
Web of Sience KeyUT 000356903000001
Title Alternative The 2013 Incentive Award of the Okayama Medical Association in Cardiovascular and Pulmonary Research (2013 Sunada Prize)
FullText URL 126_195.pdf
Author Akagi, Satoshi|
Abstract 受賞対象論文: Akagi S, Nakamura K, Matsubara H, Kusano KF, Kataoka N, Oto T, Miyaji K, Miura A, Ogawa A, Yoshida M, Ueda-Ishibashi H, Yutani C, Ito H:Prostaglandin I2 induces apoptosis via upregulation of Fas ligand in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. Int J Cardiol (2013) 165, 499-505.
Publication Title 岡山医学会雑誌
Published Date 2014-12-01
Volume volume126
Issue issue3
Start Page 195
End Page 197
ISSN 0030-1558
language 日本語
Copyright Holders Copyright (c) 2014 岡山医学会
File Version publisher
DOI 10.4044/joma.126.195
NAID 130004903242